2026-10-25
Longeveron clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,071 −0.10%
BTC $79,851 −1.18%
VIX 16.91 −3.48%
latest tape · as of 02:01 UTC
The Screen · Healthcare · Biotechnology
Longeveron Inc
LGVN · NASDAQ · USD · Market cap $5M · 38 employees
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Not yet scored1.60 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.60 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 1.60 against the desk's fair-value range, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price1.60 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Distribution2.45-34.7% to today ✓Markup gives way to Distribution after a 64% slide in 4 weeks
2026-09-04Read Markup6.78-76.4% to today Distribution gives way to Markup after a 766% rise in 9 weeks
2026-07-02Read Distribution0.78+104.4% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Longeveron Inc holds its Distribution at $1.60. Consolidating, no directional conviction, held for 6 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 6 days |
| Price at the screen | $1.60 |
| Valuation | N/A trailing · -1.05 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | -0.20 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 8.03% | Below 33% | Interest-bearing debt is just 8.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 46.44% | Below 49% | Money owed to the company is 46.4% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Longeveron clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Longeveron clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
The Street's RangeThird-party analyst targets: 2 covering, consensus None. The average target sits +3,728% from the screen price.
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -1.0x |
| EPS, trailing | -9.90 |
| EPS, forward | -1.53 |
| Revenue growth | -9.2%revenue is shrinking |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -203.6%not currently earning a positive return on equity |
| FCF yield | -227.47% |
| Debt to equity | 0.06minimal debt: a conservative balance sheet |
| Current ratio | 2.63comfortably covers its short-term bills |
| Beta | -0.20barely tracks the market's swings |
| Short interest, float | 0.04% |
| 52-week range | 1.31 - 12.30 |
| Moat | NONE |
| Market cap | $5M |
| Employees | 38 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeLGVN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-19
Distribution $1.50
-38.8% Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 38.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $7.
2026-10-02
Distribution · changed $2.45
-63.9% Entry 6
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 63.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $7.
2026-09-04
Markup · changed $6.78
+990.0% Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 990.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $7.
2026-08-04
Distribution $0.62
-20.5% Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $7.
2026-07-18
Distribution $0.78
+0.0% Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (3 analysts) rates it none, with a mean price target of $7.
2026-07-03
Distribution $0.78
+0.0% Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Distribution $0.78
Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Longeveron to Participate in Three Longevity/Aging Investment Conferences Yahoo Finance · 28d ago
- Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value? Yahoo Finance · 22 Sep 2026
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug BioPharma Dive · 18 Sep 2026
- Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug Yahoo Finance · 18 Sep 2026
- LGVN Posts Disappointing Trial Results Yahoo Finance · 17 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
LIMNLiminatus Pharma Inc
ERNAErnexa Therapeutics Inc
IMNNImunon Inc
CNSPCns Pharmaceuticals Inc
CANFCan-Fite Biopharma Ltd ADR
RNAZTransCode Therapeutics Inc
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.84 | -6.6% | · | $934 | -6.6% |
| 2 months | $1.16 | -32.5% | · | $675 | -32.5% |
| 3 months | $0.81 | -3.3% | · | $968 | -3.3% |
| 6 months | $0.63 | +24.8% | · | $1,248 | +24.8% |
| 1 year | $1.38 | -43.3% | · | $567 | -43.3% |
| 2 years | $1.06 | -26.2% | · | $738 | -26.2% |
| 3 years | $34.20 | -97.7% | · | $23 | -97.7% |
| 5 years | $70.60 | -98.9% | · | $11 | -98.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever LGVN does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.